Fred Ramsdell

from Wikipedia, the free encyclopedia

Frederick J. "Fred" Ramsdell (* 1961 ) is an American immunologist .

Ramsdell earned a BA in Biology from the University of California, San Diego in 1983 and a Ph.D. in 1987 from the University of California, Los Angeles. in immunology. As a postdoctoral fellow , he worked at the National Institutes of Health . Ramsdell went into industrial research. He held managerial positions at biotechnology companies Celltech , ZymoGenetics , Novo Nordisk and aTyr Pharma , among others . Since the beginning of 2016, Ramsdell has been research director at the Parker Institute for Cancer Immunotherapy in San Francisco .

Ramsdell identified the forkhead box protein P3 (FOXP3) in certain mice and in children with IPEX , a severe autoimmune disease . FOXP3 plays a crucial role in the development of the regulatory T cell . Further work dealt with sclerostin , a regulatory protein of bone metabolism and a target molecule of possible osteoporosis therapy.

In 2017, Ramdell received the Crafoord Prize for Polyarthritis Research together with Shimon Sakaguchi and Alexander Rudensky for “his discoveries regarding regulatory T cells that counteract harmful immune reactions in arthritis and other autoimmune diseases” .

Individual evidence

  1. ^ ATyr Pharma Appoints Fred Ramsdell, Ph.D., as Vice President, Immunology; Industry Veteran Established Immunology Research Programs at NovoNordisk, ZymoGenetics. In: firstwordpharma.com. November 5, 2014, accessed January 12, 2017 .
  2. ↑ The Crafoord Prize in Polyarthritis 2017 - Crafoordprize. In: crafoordprize.se. January 11, 2017, accessed January 12, 2017 .

Web links

personal data
SURNAME Ramsdell, Fred
ALTERNATIVE NAMES Ramsdell, Frederick J.
BRIEF DESCRIPTION American immunologist
DATE OF BIRTH 1961